Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma has received Israeli Ministry of Health approval to proceed with a Phase IIa clinical trial of Namodenoson for treating pancreatic carcinoma. The trial aims to determine the drug’s safety and efficacy in patients with advanced disease who have undergone previous treatments. Namodenoson, known for its selective action and strong safety profile, has shown promise in pre-clinical studies for its anti-cancer effects.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
